Based on the recent DDIAS studies, the strategy for developing anticancer drugs involves the development of the following agents: 1) DDIAS-reducing agents such as siRNAs, shRNAs, and ASOs; 2) direct or indirect transcriptional inhibitors of DDIAS, such as proteins that dephosphorylate NFAT2 or ERK5; 3) inhibitors of cancer-related DDIAS functions, such as DDIAS-STAT3 binding and DDIAS-FADD binding; 4) RSK2 inhibitors that cleave caspase 8; and 5) anticancer agents developed on the basis of cancer-related DDIAS function. Here, STAT3 is linked to cancer.